Table 5 Clinically significant interactions or contraindications
Interaction or contraindication | Number of prescriptions | Percentage |
|---|---|---|
NSAIDs-non-steroidal anti-inflammatory drugs | 142 | 35% |
Beta blockers or ACE/ARBs used as monotherapy in patients of African origin, | 69 | 17% |
Atenolol administered to diabetics | 53 | 13% |
Thiazide-Amiloride combination containing hydrochlorothiazide 50Â mg per tablet | 45 | 11% |
Medicines from the same therapeutic class being administered together | 31 | 8% |
Potassium sparing agents and ACE/ARBs administered together | 19 | 5% |
Hydrochlorothiazide prescribed to diabetics | 17 | 4% |
Hydrochlorothiazide prescribed to patients with gout | 13 | 3% |
Beta blockers and ACE/ARBs used as dual therapy in patients of African origin. | 11 | 3% |
Atenolol prescribed to asthmatics | 6 | 1% |
Total | 406 | 100% |